New cancer drug targets specific tumor marker in early trial
Disease control
Completed
This study tested an experimental drug called LM-302 in people with advanced solid tumors that have a specific protein marker (CLDN18.2). The main goals were to find a safe dose and see if the drug shows early signs of fighting the cancer. It involved 153 adults whose cancer had …
Phase: PHASE1, PHASE2 • Sponsor: LaNova Medicines Zhejiang Co., Ltd. • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC